SM
ATHE

Sabby Management’s Alterity Therapeutics ATHE Stock Holding History

Sabby Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,584
Closed -$249K – 159
2020
Q4 		$249K Buy
+18,584
New +$293K 0.05% 80
2014
Q2 		– Sell
-288
Closed -$48K – 260
2014
Q1 		$48K Buy
+288
New +$159K ﹤0.01% 228

Other funds holding ATHE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Sabby Management's ATHE Position: Q1 2021 in Review

Sabby Management sold out of Alterity Therapeutics (ATHE) in Q1 2021, closing a stake of 18,584 shares — an estimated $249K sold.

Sabby Management first reported a position in ATHE in Q1 2014 and held it in 2 quarters. The position peaked at $249K in Q4 2020. 12 funds tracked by Wall St. Rank hold ATHE as of Q1 2021.

  • Sabby Management reported no remaining Alterity Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 18,584 Alterity Therapeutics shares in Q1 2021, an estimated $249K.
  • Sabby Management first reported a position in Alterity Therapeutics in Q1 2014 and held it in 2 quarters.
  • Sabby Management's Alterity Therapeutics position peaked at $249K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.